Literature DB >> 1436530

Subacute necrotizing encephalopathy: oxidative phosphorylation defects and the ATPase 6 point mutation.

J M Shoffner1, P M Fernhoff, N S Krawiecki, D B Caplan, P J Holt, D A Koontz, Y Takei, N J Newman, R G Ortiz, M Polak.   

Abstract

Subacute necrotizing encephalopathy (SNE) or Leigh's disease is associated with various defects in oxidative phosphorylation (OXPHOS). However, the relationships between these OXPHOS defects and nuclear DNA or mitochondrial DNA (mtDNA) mutations is still unclear. We evaluated three SNE pedigrees (two singleton cases and a pedigree) biochemically for OXPHOS abnormalities and genetically for four mtDNA point mutations. There was a complex I defect in all three pedigrees that was associated with a complex III defect in two individuals. An mtDNA mutation in the ATPase, subunit 6 gene (np 8993) was present in one SNE pedigree. This mutation was maternally inherited, heteroplasmic, produced marked clinical and biochemical heterogeneity between pedigree members, and varied along the maternal lineage at levels ranging from 0% to > 95% of the total mtDNAs. These mtDNA mutations were not present in the other two pedigrees. These observations emphasize the importance of screening for OXPHOS defects and mtDNA mutations in SNE cases.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1436530     DOI: 10.1212/wnl.42.11.2168

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  32 in total

1.  Genetic counseling and prenatal diagnosis for the mitochondrial DNA mutations at nucleotide 8993.

Authors:  S L White; V R Collins; R Wolfe; M A Cleary; S Shanske; S DiMauro; H H Dahl; D R Thorburn
Journal:  Am J Hum Genet       Date:  1999-08       Impact factor: 11.025

2.  Mitochondrial DNA mutations at nucleotide 8993 show a lack of tissue- or age-related variation.

Authors:  S L White; S Shanske; J J McGill; H Mountain; M T Geraghty; S DiMauro; H H Dahl; D R Thorburn
Journal:  J Inherit Metab Dis       Date:  1999-12       Impact factor: 4.982

Review 3.  Diseases resulting from mitochondrial DNA point mutations.

Authors:  D C Wallace; M T Lott; J M Shoffner; M D Brown
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

4.  De novo mutation in the mitochondrial ATP synthase subunit 6 gene (T8993G) with rapid segregation resulting in Leigh syndrome in the offspring.

Authors:  M H Tulinius; M Houshmand; N G Larsson; E Holme; A Oldfors; E Holmberg; J Wahlström
Journal:  Hum Genet       Date:  1995-09       Impact factor: 4.132

5.  Skewed segregation of the mtDNA nt 8993 (T-->G) mutation in human oocytes.

Authors:  R B Blok; D A Gook; D R Thorburn; H H Dahl
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

6.  Mitochondrial gene therapy improves respiration, biogenesis, and transcription in G11778A Leber's hereditary optic neuropathy and T8993G Leigh's syndrome cells.

Authors:  Shilpa Iyer; Kristen Bergquist; Kisha Young; Erich Gnaiger; Raj R Rao; James P Bennett
Journal:  Hum Gene Ther       Date:  2012-04-17       Impact factor: 5.695

7.  Marked increase in the number and variety of mitochondrial DNA rearrangements in aging human skeletal muscle.

Authors:  S Melov; J M Shoffner; A Kaufman; D C Wallace
Journal:  Nucleic Acids Res       Date:  1995-10-25       Impact factor: 16.971

Review 8.  Mitochondrial DNA sequence variation in human evolution and disease.

Authors:  D C Wallace
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

9.  The first nuclear-encoded complex I mutation in a patient with Leigh syndrome.

Authors:  J Loeffen; J Smeitink; R Triepels; R Smeets; M Schuelke; R Sengers; F Trijbels; B Hamel; R Mullaart; L van den Heuvel
Journal:  Am J Hum Genet       Date:  1998-12       Impact factor: 11.025

10.  Clinical and laboratory findings in referrals for mitochondrial DNA analysis.

Authors:  P J Lamont; R Surtees; C E Woodward; J V Leonard; N W Wood; A E Harding
Journal:  Arch Dis Child       Date:  1998-07       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.